Aristolochic acids (AAs) are a group of naturally occurring compounds present in many plant species of the Aristolochiaceae family. Exposure to AA is a significant risk factor for severe nephropathy, and urological and hepatobiliary cancers (among others) that are often recurrent and characterized by the prominent mutational fingerprint of AA. However, herbal medicinal products that contain AA continue to be manufactured and marketed worldwide with inadequate regulation, and possible environmental exposure routes receive little attention. As the trade of food and dietary supplements becomes increasingly globalized, we propose that further inaction on curtailing AA exposure will have far-reaching negative effects on the disease trends of AA-associated cancers. Our Review aims to systematically present the historical and current evidence for the mutagenicity and carcinogenicity of AA, and the effect of removing sources of AA exposure on cancer incidence trends. We discuss the persisting challenges of assessing the scale of AA-related carcinogenicity, and the obstacles that must be overcome in curbing AA exposure and preventing associated cancers. Overall, this Review aims to strengthen the case for the implementation of prevention measures against AA's multifaceted, detrimental and potentially fully preventable effects on human cancer development.

BIOCEV 1st Faculty of Medicine Charles University Vestec Czech Republic

Department of Medical Sciences School of Medical and Life Sciences Sunway University Petaling Jaya Malaysia

Department of Pharmacological Sciences Stony Brook University Stony Brook NY USA

Epigenomics and Mechanisms Branch International Agency for Research on Cancer WHO Lyon France

Faculty of Science Charles University Prague Czech Republic

Zobrazit více v PubMed

Kumar, V., Poonam, Prasad, A. K. & Parmar, V. S. Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. Nat. Product. Rep. 20, 565–583 (2003). DOI

Han, J., Xian, Z., Zhang, Y., Liu, J. & Liang, A. Systematic overview of aristolochic acids: nephrotoxicity, carcinogenicity, and underlying mechanisms. Front. Pharmacol. 10, 648 (2019). PubMed DOI PMC

Michl, J. et al. LC-MS- and DOI

Michl, J., Bello, O., Kite, G. C., Simmonds, M. S. J. & Heinrich, M. Medicinally used Asarum species: high-resolution LC-MS analysis of aristolochic acid analogs and in vitro toxicity screening in HK-2 cells. Front. Pharmacol. https://doi.org/10.3389/fphar.2017.00215 (2017). PubMed DOI PMC

Scarborough, J. & Fernandes, A. Ancient medicinal use of Aristolochia: Birthwort’s tradition and toxicity. Pharm. Hist. 53, 3–21 (2011). PubMed

Tomlinson, T., Fernandes, A. & Grollman, A. P. Aristolochia herbs and iatrogenic disease: the case of Portland’s powders. Yale J. Biol. Med. 93, 355–363 (2020). PubMed PMC

Grollman, A. P., Scarborough, J. & Jelaković, B. In: Advances in Molecular Toxicology Vol. 3 211–227 (Elsevier, 2009).

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. Volume 100A. A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 100, 1–401 (2012). In this volume of the IARC Monographs, the Working Group on the Evaluation of Carcinogenic Risks to Humans conducts a re-evaluation of AA and determines that the evidence available warrants its classification as a group 1 carcinogen. PMC

Gold, L. S. & Slone, T. H. Aristolochic acid, an herbal carcinogen, sold on the web after FDA alert. N. Engl. J. Med. 349, 1576–1577 (2003). PubMed DOI

Arlt, V. M., Stiborova, M. & Schmeiser, H. H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17, 265–277 (2002). PubMed DOI

Ng, A. W. et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci. Transl. Med. 9, eaan6446 (2017). This study reports that an alarmingly high proportion (78%) of HCCs from patients treated in Taiwan harboured the AA mutational signature, and was among the first to examine the disparities in the occurrence of the AA mutational signature between patients with HCC in different countries. PubMed DOI

Martena, M. J. et al. Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Anal. Bioanal. Chem. 389, 263–275 (2007). PubMed DOI

Debelle, F. D., Vanherweghem, J.-L. & Nortier, J. L. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74, 158–169 (2008). PubMed DOI

Wu, L. et al. An integrated system for identifying the hidden assassins in traditional medicines containing aristolochic acids. Sci. Rep. 5, 11318 (2015). PubMed DOI PMC

Zhang, H. M. et al. Recognition of the toxicity of aristolochic acid. J. Clin. Pharm. Ther. 44, 157–162 (2019). PubMed DOI

Vaclavik, L., Krynitsky, A. J. & Rader, J. I. Quantification of aristolochic acids I and II in herbal dietary supplements by ultra-high-performance liquid chromatography–multistage fragmentation mass spectrometry. Food Addit. Contam. Part. A Chem. Anal. Control. Expo. Risk Assess. 31, 784–791 (2014). PubMed DOI

Schaneberg, B. T. & Khan, I. A. Analysis of products suspected of containing Aristolochia or Asarum species. J. Ethnopharmacol. 94, 245–249 (2004). PubMed DOI

Cachet, X. et al. Detection of aristolochic acids I and II in “Chiniy-trèf”, a traditional medicinal preparation containing caterpillars feeding on Aristolochia trilobata L. in Martinique, French West Indies. Toxicon https://doi.org/10.1016/j.toxicon.2016.02.013 (2016). PubMed DOI

Riffault-Valois, L. et al. Health risk associated with the oral consumption of “Chiniy-tref”, a traditional medicinal preparation used in Martinique (French West Indies): qualitative and quantitative analyses of aristolochic acids contained therein. Toxicon 172, 53–60 (2019). PubMed DOI

Ioset, J. R., Raoelison, G. E. & Hostettmann, K. Detection of aristolochic acid in Chinese phytomedicines and dietary supplements used as slimming regimens. Food Chem. Toxicol. 41, 29–36 (2003). PubMed DOI

Cheung, T. P., Xue, C., Leung, K., Chan, K. & Li, C. G. Aristolochic acids detected in some raw Chinese medicinal herbs and manufactured herbal products — a consequence of inappropriate nomenclature and imprecise labelling? Clin. Toxicol. 44, 371–378 (2006). DOI

Abdullah, R., Diaz, L. N., Wesseling, S. & Rietjens, I. M. C. M. Risk assessment of plant food supplements and other herbal products containing aristolochic acids using the margin of exposure (MOE) approach. Food Addit. Contam. Part. A 34, 135–144 (2017).

Liu, J., Liu, Y., Wu, Y., Dai, Z. & Ma, S. Rapid analysis of aristolochic acid analogues in traditional Chinese patent medicine by LC-MS/MS. J. Anal. Methods Chem. Anal. Control Expo. Risk Assess. 2020, 8823596 (2020).

Michl, J. et al. Is aristolochic acid nephropathy a widespread problem in developing countries?: a case study of Aristolochia indica L. in Bangladesh using an ethnobotanical–phytochemical approach. J. Ethnopharmacol. 149, 235–244 (2013). PubMed DOI

Maggini, V., Menniti-Ippolito, F. & Firenzuoli, F. Aristolochia, a nephrotoxic herb, still surfs on the Web, 15 years later. Intern. Emerg. Med. 13, 811–813 (2018). PubMed DOI

Shibutani, S. et al. Selective toxicity of aristolochic acids I and II. Drug Metab. Dispos. 35, 1217–1222 (2007). PubMed DOI

Kucab, J. E. et al. A compendium of mutational signatures of environmental agents. Cell 177, 821–836.e16 (2019). PubMed DOI PMC

Wu, S. Two cases of acute renal failure caused by mutong. Jiang Xi Zhong Yi 10, 12–14 (1964).

Hong, Y., Huang, Y. & Wang, Y. Over-dose of mutong causes renal failure and death. Zhe Jiang Zhong Yi Za Zhi 8, 32 (1965).

Zhou, F., Lu, H. & Nie, C. Toxicity of mutong causes acute renal failure. Zhonghua Shenzanbing Za Zhi 4, 223–224 (1988).

Poon, W.-T., Lai, C.-K. & Chan, A. Y.-W. Aristolochic acid nephropathy: the Hong Kong perspective. Hong. Kong J. Nephrol. 9, 7–14 (2007). DOI

Jackson, L., Kofman, S., Weiss, A. & Brodovsky, H. Aristolochic acid (Nsc-50413): phase I clinical study. Cancer Chemother. Rep. 42, 35–37 (1964). PubMed

Kupchan, S. M. & Doskotch, R. W. Tumor inhibitors. I. Aristolochic acid, the active principle of Aristolochia indica. J. Med. Pharm. Chem. 91, 657–659 (1962). PubMed DOI

Ivić, M. Etiology of endemic nephropathy. Lijec. Vjesn. 91, 1273–1281 (1969). PubMed

Vanherweghem, J.-L. et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341, 387–391 (1993). PubMed DOI

Vanherweghem, J.-L. Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J. Altern. Complement. Med. 4, 9–13 (1998). PubMed DOI

Depierreux, M., Van Damme, B., Houte, K. V. & Vanherweghem, J. L. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am. J. Kidney Dis. 24, 172–180 (1994). PubMed DOI

Cosyns, J. P. et al. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int. 45, 1680–1688 (1994). The authors examine the renal cortex specimens from individuals affected by the Belgian outbreak of AAN and report the first link connecting AAN to endemic nephropathy. PubMed DOI

Nortier, J. L. et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342, 1686–1692 (2000). This study reports that patients with AAN face a high risk of developing urothelial carcinoma. PubMed DOI

Cosyns, J.-P., Jadoul, M., Squifflet, J.-P., Wese, F.-X. & van Ypersele de Strihou, C. Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis. 33, 1011–1017 (1999). PubMed DOI

Lemy, A. et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am. J. Kidney Dis. 51, 471–477 (2008). PubMed DOI

Sun, M. et al. Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China. Ren. Fail. 37, 209–213 (2015). PubMed DOI

Yang, C.-S., Lin, C.-H., Chang, S.-H. & Hsu, H.-C. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am. J. Kidney Dis. 35, 313–318 (2000). PubMed DOI

Wu, Y., Liu, Z., Hu, W. & Li, L. Mast cell infiltration associated with tubulointerstitial fibrosis in chronic aristolochic acid nephropathy. Hum. Exp. Toxicol. 24, 41–47 (2005). PubMed DOI

Zhang, J., Zhang, L., Wang, W. & Wang, H. Association between aristolochic acid and CKD: a cross-sectional survey in China. Am. J. Kidney Dis. 61, 918–922 (2013). PubMed DOI

Pena, J. M., Borras, M., Ramos, J. & Montoliu, J. Rapidly progressive interstitial renal fibrosis due to a chronic intake of a herb (Aristolochia pistolochia) infusion. Nephrol. Dial. Transpl. 11, 1359–1360 (1996). DOI

Stengel, B. & Jones, E. End-stage renal insufficiency associated with Chinese herbal consumption in France [French]. Nephrologie 19, 15–20 (1998). PubMed

Krumme, B., Endmeir, R., Vanhaelen, M. & Walb, D. Reversible Fanconi syndrome after ingestion of a Chinese herbal ‘remedy’ containing aristolochic acid. Nephrol. Dial. Transpl. 16, 400–402 (2001). DOI

Kazama, I. et al. Adult onset Fanconi syndrome: extensive tubulo-interstitial lesions and glomerulopathy in the early stage of Chinese herbs nephropathy. Clin. Exp. Nephrol. 8, 283–287 (2004). PubMed DOI

Meyer, M. M., Chen, T. P. & Bennett, W. M. Chinese herb nephropathy. Proc. (Bayl. Univ. Med. Cent.) 13, 334–337 (2000).

Lee, S. et al. Fanconi’s syndrome and subsequent progressive renal failure caused by a Chinese herb containing aristolochic acid. Nephrology 9, 126–129 (2004). PubMed DOI

Schmeiser, H. H., Bieler, C. A., Wiessler, M., de Strihou, C. V. Y. & Cosyns, J.-P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56, 2025–2028 (1996). This study establishes the presence of AL–DNA adducts in renal tissue obtained from patients of the Belgian outbreak of AAN, implicating AA as the agent responsible for the observed nephropathy. PubMed

Stiborová, M., Frei, E., Breuer, A., Bieler, C. A. & Schmeiser, H. H. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp. Toxicol. Pathol. 51, 421–427 (1999). PubMed DOI

Lord, G. M. et al. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358, 1515–1516 (2001). PubMed DOI

Bieler, C. A. et al. PubMed DOI

Lo, S. H. et al. Detection of Herba Aristolochia Mollissemae in a patient with unexplained nephropathy. Am. J. Kidney Dis. 45, 407–410 (2005). PubMed DOI

Chen, C.-H. et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl Acad. Sci. USA 109, 8241–8246 (2012). This breakthrough molecular epidemiology study in East Asia establishes the significant contribution of exposure to AA to the high incidence of UTUC, using the characteristic molecular markers of exposure and its impact. PubMed DOI PMC

Yun, B. H. et al. Biomonitoring of aristolactam–DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem. Res. Toxicol. 25, 1119–1131 (2012). PubMed DOI PMC

Lord, G. M. et al. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 43, e18.11–e18.17 (2004). DOI

Chen, H. Y., Ma, B.-Y., Grant, A. & Lampert, N. Time to abandon the term “Chinese herbs nephropathy”. Kidney Int. 60, 2039–2040 (2001). PubMed DOI

Gillerot, G. et al. Aristolochic acid nephropathy in a Chinese patient: time to abandon the term “Chinese herbs nephropathy”? Am. J. Kidney Dis. 38, E26 (2001). PubMed DOI

Grollman, A. P. et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl Acad. Sci. USA 104, 12129 (2007). This molecular epidemiology study establishes dietary exposure to AA from environmental sources as a significant risk factor for BEN and associated urothelial carcinomas. PubMed DOI PMC

Jelaković, B. et al. Aristolactam–DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 81, 559–567 (2012). This work describes the occurrence of AL–DNA adducts and the TP53 AA mutational spectrum in the UTUC of patients who resided in the endemic region. PubMed DOI

Arlt, V. M. et al. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int. J. Cancer 101, 500–502 (2002). PubMed DOI

Batuman, V. Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers. Kidney Int. 69, 644–646 (2006). PubMed DOI

Hranjec, T. et al. Endemic nephropathy: the case for chronic poisoning by Aristolochia. Croat. Med. J. 46, 116–125 (2005). PubMed

Hsieh, S.-C., Lin, I.-H., Tseng, W.-L., Lee, C.-H. & Wang, J.-D. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin. Med. 3, 1–6 (2008). DOI

Lai, M.-N. et al. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case–control study. Am. J. Kidney Dis. 55, 507–518 (2010). PubMed DOI

Lai, M.-N., Wang, S.-M., Chen, P.-C., Chen, Y.-Y. & Wang, J.-D. Population-based case–control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J. Natl Cancer Inst. 102, 179–186 (2010). This case–control study examines the association between prescription of AA-containing herbal products and urinary tract cancer in Taiwan, reporting that consumption of AA-containing herbal products is associated with an increased risk of urinary tract cancer. PubMed DOI PMC

Hoang, M. L. et al. Aristolochic acid in the etiology of renal cell carcinoma. Cancer Epidemiol. Prev. Biomark. 25, 1600–1608 (2016). DOI

Yang, H.-y, Wang, J.-D., Lo, T.-C. & Chen, P.-C. Increased mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists. J. Epidemiol. Jpn. Epidemiol. Assoc. 19, 17–23 (2009). DOI

Yang, H.-Y., Wang, J.-D., Lo, T.-C. & Chen, P.-C. Increased risks of upper tract urothelial carcinoma in male and female Chinese herbalists. J. Formos. Med. Assoc. 110, 161–168 (2011). This study reports that herbalists in Taiwan had a significantly higher risk of developing upper tract urothelial, renal and bladder cancers. PubMed DOI

Yang, H.-Y., Wang, J.-D., Lo, T.-C. & Chen, P.-C. Occupational kidney disease among Chinese herbalists exposed to herbs containing aristolochic acids. Occup. Environ. Med. 68, 286–290 (2011). PubMed DOI

Yang, H.-Y., Wang, J.-D., Lo, T.-C. & Chen, P.-C. Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists. J. Urol. 189, 48–52 (2013). Following up on a previous study (ref. 73), the authors determine that having processed, sold or dispensed herbs containing fangchi significantly increases the risk of developing urothelial carcinoma in Chinese herbalists. PubMed DOI

Chen, C.-J. et al. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Int. J. Cancer 143, 1578–1587 (2018). This study reports a significant dose–response relationship between the consumption of AA-containing herbs and the risk of developing HCC among patients infected with HBV. PubMed DOI

Chen, C. J. et al. Herbal medicine containing aristolochic acid and the risk of primary liver cancer in patients with hepatitis C virus infection. Cancer Epidemiol. Biomark. Prev. 28, 1876–1883 (2019). This study reports a significant dose–response relationship between the consumption of AA-containing herbs and the risk of developing primary liver cancers among patients infected with HCV. DOI

Chen, C. J. et al. Aristolochic acid and the risk of cancers in patients with type 2 diabetes: nationwide population-based cohort study. Phytomedicine 99, 154023 (2022). This study reports that the use of AA-containing herbs is associated with a significantly higher risk of developing liver, colorectum, kidney, bladder, prostate, pelvis and ureter cancers in patients with diabetes. PubMed DOI

Hollstein, M., Moriya, M., Grollman, A. P. & Olivier, M. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat. Res. 753, 41–49 (2013). PubMed DOI PMC

Mengs, U. Tumour induction in mice following exposure to aristolochic acid. Arch. Toxicol. 61, 504–505 (1988). PubMed DOI

Mengs, U., Lang, W. & Poch, J. A. The carcinogenic action of aristolochic acid in rats. Arch. Toxicol. 51, 107–119 (1982). DOI

Mengs, U. On the histopathogenesis of rat forestomach carcinoma caused by aristolochic acid. Arch. Toxicol. 52, 209–220 (1983). PubMed DOI

Hwang, M. S. et al. Subchronic toxicity studies of the aqueous extract of Aristolochiae fructus in Sprague-Dawley rats. J. Toxicol. Env. Health A 69, 2157–2165 (2006). DOI

Schmeiser, H. H. et al. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res. 50, 5464–5469 (1990). PubMed

Lu, Z. N. et al. The mutational features of aristolochic acid–induced mouse and human liver cancers. Hepatology 71, 929–942 (2020). PubMed DOI

Jadot, I., Declèves, A.-E., Nortier, J. & Caron, N. An integrated view of aristolochic acid nephropathy: update of the literature. Int. J. Mol. Sci. 18, 297 (2017). DOI PMC

National Toxicology Program. Aristolochic acids. Rep. Carcinog. 12, 45–49 (2011).

Chang, S. Y. et al. Human liver–kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight https://doi.org/10.1172/jci.insight.95978 (2017). PubMed DOI PMC

Hashimoto, K. et al. Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells. Carcinogenesis 37, 647–655 (2016). PubMed DOI PMC

Sidorenko, V. S. Biotransformation and toxicities of aristolochic acids. Adv. Exp. Med. Biol. 1241, 139–166 (2020). PubMed DOI

Sidorenko, V. S. et al. Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis 35, 1814–1822 (2014). PubMed DOI PMC

Stiborova, M., Martinek, V., Frei, E., Arlt, V. M. & Schmeiser, H. H. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. Curr. Drug Metab. 14, 695–705 (2013). PubMed DOI

Okuno, Y. et al. Bioactivation mechanisms of N-hydroxyaristolactams: nitroreduction metabolites of aristolochic acids. Environ. Mol. Mutagen. 60, 792–806 (2019). PubMed DOI PMC

Arlt, V. M. et al. Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. Arch. Toxicol. 91, 1957–1975 (2017). PubMed DOI

Pfau, W., Schmeiser, H. H. & Wiessler, M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 11, 313–319 (1990). PubMed DOI

Attaluri, S. et al. DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res. 38, 339–352 (2010). PubMed DOI

Broschard, T. H., Wiessler, M., von der Lieth, C.-W. & Schmeiser, H. H. Translesional synthesis on DNA templates containing site-specifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant carcinogen aristolochic acid. Carcinogenesis 15, 2331–2340 (1994). PubMed DOI

Schmeiser, H. H. et al. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int. J. Cancer 135, 502–507 (2014). PubMed DOI

Liu, Y., Chan, C. K., Jin, L., Wong, S. K. & Chan, W. Quantitation of DNA adducts in target and nontarget organs of aristolochic acid I-exposed rats: correlating DNA adduct levels with organotropic activities. Chem. Res. Toxicol. 32, 397–399 (2019). PubMed DOI

Fernando, R. C., Schmeiser, H. H., Scherf, H. R. & Wiessler, M. Formation and persistence of specific purine DNA adducts by

Sidorenko, V. S. et al. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam–DNA adducts. Nucleic Acids Res. 40, 2494–2505 (2012). PubMed DOI

Lukin, M., Zaliznyak, T., Johnson, F. & de los Santos, C. Structure and stability of DNA containing an aristolactam II–dA lesion: implications for the NER recognition of bulky adducts. Nucleic Acids Res. 40, 2759–2770 (2012). PubMed DOI

Hashimoto, K., Bonala, R., Johnson, F., Grollman, A. P. & Moriya, M. Y-family DNA polymerase-independent gap-filling translesion synthesis across aristolochic acid-derived adenine adducts in mouse cells. DNA Repair. 46, 55–60 (2016). PubMed DOI PMC

Poon, S. L. et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 5, 197ra101–197ra101 (2013). This study provides one of the first descriptions of the AA mutational signature on a genome-wide scale in mice and humans. PubMed DOI

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013). PubMed DOI PMC

Moriya, M. et al. TP53 mutational signature for aristolochic acid: an environmental carcinogen. Int. J. Cancer 129, 1532–1536 (2011). PubMed DOI

Hoang, M. L. et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 5, 197ra102–197ra102 (2013). This study describes the AA mutational signature in UTUC in individuals with documented exposure to AA, illustrating the mutagenicity of AA in humans and providing one of the first descriptions of the AA mutational signature on a genome-wide scale. PubMed DOI PMC

Rosenquist, T. A. & Grollman, A. P. Mutational signature of aristolochic acid: clue to the recognition of a global disease. DNA Repair. 44, 205–211 (2016). PubMed DOI

Castells, X. et al. Low-coverage exome sequencing screen in formalin-fixed paraffin-embedded tumors reveals evidence of exposure to carcinogenic aristolochic acid. Cancer Epidemiol. Prev. Biomark. 24, 1873–1881 (2015). This study describes a protocol for conducting low-coverage whole-exome sequencing that can reliably detect the AA mutational signature, among other signatures, in archival FFPE urothelial tumours. DOI

Lu, H. et al. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma. Theranostics 10, 4323–4333 (2020). The authors conduct whole-genome sequencing on 90 upper tract urothelial cancers from patients residing in China that were not preselected for documented AA consumption, and report that 27 harboured the AA mutational signature and that the mutational signature may be detected in urinary cell-free DNA. PubMed DOI PMC

Poon, S. L. et al. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med. 7, 1–10 (2015). DOI

Lai, H.-Y. et al. High level of aristolochic acid detected with a unique genomic landscape predicts early UTUC onset after renal transplantation in Taiwan. Front. Oncol. 11, 828314–828314 (2022). PubMed DOI PMC

Scelo, G. et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat. Commun. 5, 1–13 (2014). This study presents whole-genome sequences of ccRCCs from four European countries, identifying the AA mutational signature in cancers originating from patients from Romania but outside the previously reported endemic region. DOI

Turesky, R. J. et al. Aristolochic acid exposure in Romania and implications for renal cell carcinoma. Br. J. Cancer 114, 76–80 (2016). Following up on the earlier report by Scelo et al. (2014), the authors detect the AL–DNA adduct in non-tumour renal tissue from the AA-associated Romanian RCC cases reported by Scelo et al., concluding that AA exposure occurs and is responsible for causing AA-associated diseases in Europe outside the previously reported endemic region. PubMed DOI

Jelaković, B. et al. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int. J. Cancer 136, 2967–2972 (2015). PubMed DOI

Letouzé, E. et al. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat. Commun. 8, 1315 (2017). PubMed DOI PMC

Lin, J. et al. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics 11, 4585–4598 (2021). PubMed DOI PMC

Zou, S. et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696 (2014). PubMed DOI

Moody, S. et al. Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. Nat. Genet. 53, 1553–1563 (2021). PubMed DOI

Cui, Y. et al. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res. 30, 902–913 (2020). PubMed DOI PMC

Du, Y. et al. Mutagenic factors and complex clonal relationship of multifocal urothelial cell carcinoma. Eur. Urol. 71, 841–843 (2017). PubMed DOI

Guo, G. et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 45, 1459–1463 (2013). PubMed DOI PMC

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014). DOI

Li, R. et al. Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science 370, 82–89 (2020). PubMed DOI

Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 75–82 (2020). PubMed DOI

Hoang, M. L. et al. Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proc. Natl Acad. Sci. USA 113, 9846 (2016). PubMed DOI PMC

Sung, W. K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44, 765–769 (2012). PubMed DOI

Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327–1341.e23 (2017). DOI

Candia, J. et al. The genomic landscape of Mongolian hepatocellular carcinoma. Nat. Commun. 11, 4383 (2020). PubMed DOI PMC

Li, R. et al. A body map of somatic mutagenesis in morphologically normal human tissues. Nature 597, 398–403 (2021). PubMed DOI

Zhai, W. et al. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. Nat. Sci. Rev. 9, nwab192 (2021). DOI

Lim, A. H. et al. Rare occurrence of aristolochic acid mutational signatures in oro-gastrointestinal tract cancers. Cancers 14, 576 (2022). PubMed DOI PMC

Nik-Zainal, S. et al. The genome as a record of environmental exposure. Mutagenesis 30, 763–770 (2015). PubMed PMC

Olivier, M. et al. Modelling mutational landscapes of human cancers in vitro. Sci. Rep. 4, 1–9 (2014). DOI

Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020). PubMed DOI PMC

Blokzijl, F., Janssen, R., van Boxtel, R. & Cuppen, E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med. 10, 33 (2018). PubMed DOI PMC

Islam, S. M. A. & Alexandrov, L. B. Bioinformatic methods to identify mutational signatures in cancer. Methods Mol. Biol. 2185, 447–473 (2021). PubMed DOI

Degasperi, A. et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science https://doi.org/10.1126/science.abl9283 (2022). PubMed DOI PMC

Karanović, S. et al. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure. Int. J. Cancer 150, 374–386 (2022). PubMed DOI

Chen, C.-H. et al. Additive effects of arsenic and aristolochic acid in chemical carcinogenesis of upper urinary tract urothelium. Cancer Epidemiol. Biomark. Prev. 30, 317 (2021). DOI

Zhang, M., Liu, H., Han, Y., Bai, L. & Yan, H. A review on the pharmacological properties, toxicological characteristics, pathogenic mechanism and analytical methods of aristolochic acids. Toxin Rev. 30, 1–10 (2020).

Chan, W., Lee, K.-C., Liu, N. & Cai, Z. A sensitivity enhanced high-performance liquid chromatography fluorescence method for the detection of nephrotoxic and carcinogenic aristolochic acid in herbal medicines. J. Chromatogr. A 1164, 113–119 (2007). PubMed DOI

de Boer, H. J., Ichim, M. C. & Newmaster, S. G. DNA barcoding and pharmacovigilance of herbal medicines. Drug Saf. 38, 611–620 (2015). PubMed DOI

Li, M. et al. Molecular identification and cytotoxicity study of herbal medicinal materials that are confused by Aristolochia herbs. Food Chem. 147, 332–339 (2014). PubMed DOI

Sgamma, T., Masiero, E., Mali, P., Mahat, M. & Slater, A. Sequence-specific detection of Aristolochia DNA — a simple test for contamination of herbal products. Front. Plant Sci. 9, 1828–1828 (2018). PubMed DOI PMC

Dechbumroong, P., Aumnouypol, S., Denduangboripant, J. & Sukrong, S. DNA barcoding of Aristolochia plants and development of species-specific multiplex PCR to aid HPTLC in ascertainment of Aristolochia herbal materials. PloS ONE 13, e0202625 (2018). PubMed DOI PMC

Wu, L. et al. Rapid identification of officinal Akebiae Caulis and its toxic adulterant Aristolochiae Manshuriensis Caulis (Aristolochia manshuriensis) by loop-mediated isothermal amplification. Front. Plant. Sci. 7, 887–887 (2016). PubMed DOI PMC

Raclariu, A. C., Heinrich, M., Ichim, M. C. & de Boer, H. Benefits and limitations of DNA barcoding and metabarcoding in herbal product authentication. Phytochem. Anal. 29, 123–128 (2018). PubMed DOI

Bruni, I. et al. Identification of poisonous plants by DNA barcoding approach. Int. J. Leg. Med. 124, 595–603 (2010). DOI

Yun, B. H., Bellamri, M., Rosenquist, T. A. & Turesky, R. J. Method for biomonitoring DNA adducts in exfoliated urinary cells by mass spectrometry. Anal. Chem. 90, 9943–9950 (2018). PubMed DOI PMC

Guo, J. et al. Multiclass carcinogenic DNA adduct quantification in formalin-fixed paraffin-embedded tissues by ultraperformance liquid chromatography–tandem mass spectrometry. Anal. Chem. 88, 4780–4787 (2016). PubMed DOI PMC

Yun, B. H. et al. Human formalin-fixed paraffin-embedded tissues: an untapped specimen for biomonitoring of carcinogen DNA adducts by mass spectrometry. Anal. Chem. 85, 4251–4258 (2013). PubMed DOI PMC

Yun, B. H. et al. Formalin-fixed paraffin-embedded tissue as a source for quantitation of carcinogen DNA adducts: aristolochic acid as a prototype carcinogen. Carcinogenesis 35, 2055–2061 (2014). PubMed DOI PMC

Abascal, F. et al. Somatic mutation landscapes at single-molecule resolution. Nature 593, 405–410 (2021). PubMed DOI

Kennedy, S. R. et al. Detecting ultralow-frequency mutations by duplex sequencing. Nat. Protoc. 9, 2586–2606 (2014). PubMed DOI PMC

Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat. Rev. Genet. 19, 269–285 (2018). PubMed DOI PMC

Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508–14513 (2012). PubMed DOI PMC

Guo, L. et al. A novel and specific method for the determination of aristolochic acid-derived DNA adducts in exfoliated urothelial cells by using ultra performance liquid chromatography–triple quadrupole mass spectrometry. J. Chromatogr. B 879, 153–158 (2011). DOI

Yun, B. H. et al. New approaches for biomonitoring exposure to the human carcinogen aristolochic acid. Toxicol. Res. 4, 763–776 (2015). DOI

Leung, E. M. K. & Chan, W. Noninvasive measurement of aristolochic acid–DNA adducts in urine samples from aristolochic acid-treated rats by liquid chromatography coupled tandem mass spectrometry: evidence for DNA repair by nucleotide-excision repair mechanisms. Mutat. Res. Fund. Mol. Mech. Mutagen. 766–767, 1–6 (2014). DOI

Leung, E. M. K. & Chan, W. Quantification of aristolochic acid–RNA adducts in the urine of aristolochic acid-treated rats by liquid chromatography–tandem mass spectrometry. Chem. Res. Toxicol. 28, 567–569 (2015). PubMed DOI

Springer, S. U. et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. eLife 7, e32143 (2018). PubMed DOI PMC

Phillips, D. H. Mutational spectra and mutational signatures: insights into cancer aetiology and mechanisms of DNA damage and repair. DNA Repair. 71, 6–11 (2018). PubMed DOI PMC

Zhivagui, M. et al. Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans. Genome Res. 29, 521–531 (2019). PubMed DOI PMC

Nassar, D., Latil, M., Boeckx, B., Lambrechts, D. & Blanpain, C. Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat. Med. 21, 946–954 (2015). PubMed DOI

Westcott, P. M. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489–492 (2015). PubMed DOI

McCreery, M. Q. et al. Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nat. Med. 21, 1514–1520 (2015). PubMed DOI PMC

Ng, S. W. K. et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature 598, 473–478 (2021). PubMed DOI

Popovska-Jankovic, K. et al. microRNA profiling in patients with upper tract urothelial carcinoma associated with Balkan endemic nephropathy. BioMed. Res. Int. 2016, 7450461 (2016). PubMed DOI PMC

Tao, L. et al. Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. Mol. Med. Rep. 12, 6533–6546 (2015). PubMed DOI PMC

Wang, S.-M. et al. Increased upper and lower tract urothelial carcinoma in patients with end-stage renal disease: a nationwide cohort study in Taiwan during 1997–2008. BioMed. Res. Int. 2014, 149750–149750 (2014). PubMed PMC

Jhuang, J.-R., Chiang, C.-J., Su, S.-Y., Yang, Y.-W. & Lee, W.-C. Reduction in the incidence of urological cancers after the Ban on chinese Herbal products containing aristolochic acid: an interrupted time-series analysis. Sci. Rep. 9, 1–8 (2019). This study provides the first look into disease trends following the prohibition of AA-containing herbal products in Taiwan, showing a possible reduction in incidence rates of bladder cancer, carcinomas of the renal pelvis and other urinary organs consequent to the implementation of these prohibitions. DOI

Fan, Y., Li, Z. & Xi, J. Recent developments in detoxication techniques for aristolochic acid-containing traditional Chinese medicines. RSC Adv. 10, 1410–1425 (2020). PubMed DOI PMC

Rebhan, K., Ertl, I. E., Shariat, S. F., Grollman, A. P. & Rosenquist, T. Aristolochic acid and its effect on different cancers in uro-oncology. Curr. Opin. Urol. 30, 689–695 (2020). PubMed

Stiborová, M., Arlt, V. M. & Schmeiser, H. H. Balkan endemic nephropathy: an update on its aetiology. Arch. Toxicol. 90, 2595–2615 (2016). PubMed DOI PMC

Chan, C.-K., Liu, Y., Pavlović, N. M. & Chan, W. Aristolochic acids: newly identified exposure pathways of this class of environmental and food-borne contaminants and its potential link to chronic kidney diseases. Toxics 7, 14 (2019). DOI PMC

Heinrich, M., Chan, J., Wanke, S., Neinhuis, C. & Simmonds, M. S. Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2 — a global assessment based on bibliographic sources. J. Ethnopharmacol. 125, 108–144 (2009). PubMed DOI

Chan, W. et al. Quantitation of aristolochic acids in corn, wheat grain, and soil samples collected in Serbia: identifying a novel exposure pathway in the etiology of Balkan endemic nephropathy. J. Agric. Food Chem. 64, 5928–5934 (2016). PubMed DOI

Tung, K.-K. et al. Occurrence and environmental stability of aristolochic acids in groundwater collected from Serbia: links to human exposure and Balkan endemic nephropathy. Environ. Sci. Technol. 54, 1554–1561 (2020). PubMed DOI

Li, W., Hu, Q. & Chan, W. Uptake and accumulation of nephrotoxic and carcinogenic aristolochic acids in food crops grown in Aristolochia clematitis-contaminated soil and water. J. Agric. Food Chem. 64, 107–112 (2016). PubMed DOI

Pavlović, N. M. et al. Possible health impacts of naturally occurring uptake of aristolochic acids by maize and cucumber roots: links to the etiology of endemic (Balkan) nephropathy. Environ. Geochem. Health 35, 215–226 (2013). PubMed DOI

Lukinich-Gruia, A. T. et al. Aristolochic acid I as an emerging biogenic contaminant involved in chronic kidney diseases: a comprehensive review on exposure pathways, environmental health issues and future challenges. Chemosphere 297, 134111 (2022). PubMed DOI

Chan, C.-K., Tung, K.-K., Pavlović, N. M. & Chan, W. Remediation of aristolochic acid-contaminated soil by an effective advanced oxidation process. Sci. Total. Environ. 720, 137528 (2020). PubMed DOI

Li, W. et al. Aristolochic acids as persistent soil pollutants: determination of risk for human exposure and nephropathy from plant uptake. J. Agric. Food Chem. 66, 11468–11476 (2018). PubMed DOI PMC

Wu, K. M., Farrelly, J. G., Upton, R. & Chen, J. Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. Phytomedicine 14, 273–279 (2007). PubMed DOI

Grollman, A. P. & Marcus, D. M. Global hazards of herbal remedies: lessons from Aristolochia. EMBO Rep. 17, 619–625 (2016). PubMed DOI PMC

Brunner, S. F. et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature 574, 538–542 (2019). PubMed DOI PMC

Zlotta, A. R. et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non–muscle-invasive bladder cancer. Eur. Urol. 59, 1026–1031 (2011). PubMed DOI

Chen, C.-H. et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int. J. Cancer 133, 14–20 (2013). PubMed DOI

Cosyns, J.-P. et al. Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Arch. Toxicol. 72, 738–743 (1998). PubMed DOI

Debelle, F. D. et al. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J. Am. Soc. Nephrol. 13, 431–436 (2002). PubMed DOI

Qiu, Q., Liu, Z. H., Chen, H. P., Yin, H. L. & Li, L. S. Long-term outcome of acute renal injury induced by Aristolochia manshuriensis Kom in rats. Acta Pharmacol. Sin. 21, 1129–1135 (2000). PubMed

Cui, M. Tumour induction in rats following exposure to short-term high dose aristolochic acid I. Mutagenesis 20, 45–49 (2005). PubMed DOI

Hadjiolov, D. et al. Effect of diallyl sulfide on aristolochic acid-induced forestomach carcinogenesis in rats. Carcinogenesis 14, 407–410 (1993). PubMed DOI

Cosyns, J.-P. et al. Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int. 59, 2164–2173 (2001). PubMed DOI

Kohara, A., Suzuki, T., Honma, M., Ohwada, T. & Hayashi, M. Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (Muta™Mouse). Mutat. Res. Genet. Toxicol. Environ. Mutagen. 515, 63–72 (2002). DOI

Li, X.-L., Guo, X.-Q., Wang, H.-R., Chen, T. & Mei, N. Aristolochic acid-induced genotoxicity and toxicogenomic changes in rodents. World J. Tradit. Chin. Med. 6, 12–25 (2020). PubMed DOI PMC

Chen, Y.-Y. et al. Aristolochic acid suppresses DNA repair and triggers oxidative DNA damage in human kidney proximal tubular cells. Oncol. Rep. 24, 141–153 (2010). PubMed

Yu, F.-Y., Wu, T.-S., Chen, T.-W. & Liu, B.-H. Aristolochic acid I induced oxidative DNA damage associated with glutathione depletion and ERK1/2 activation in human cells. Toxicol. Vitr. 25, 810–816 (2011). DOI

Nitzsche, D., Melzig, M. F. & Arlt, V. M. Evaluation of the cytotoxicity and genotoxicity of aristolochic acid I–A component of Aristolochiaceae plant extracts used in homeopathy. Environ. Toxicol. Pharmacol. 35, 325–334 (2013). PubMed DOI

Bastek, H. et al. Comparison of aristolochic acid I derived DNA adduct levels in human renal toxicity models. Toxicology 420, 29–38 (2019). PubMed DOI

Liu, X. et al. Mitochondrial dysfunction is involved in aristolochic acid I-induced apoptosis in renal proximal tubular epithelial cells. Hum. Exp. Toxicol. 39, 673–682 (2020). PubMed DOI

Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019). PubMed DOI

Mengs, U. Acute toxicity of aristolochic acid in rodents. Arch. Toxicol. 59, 328–331 (1987). PubMed DOI

Mengs, U. & Stotzem, C. D. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch. Toxicol. 67, 307–311 (1993). PubMed DOI

Jiang, Z. et al. Possible role of mtDNA depletion and respiratory chain defects in aristolochic acid I-induced acute nephrotoxicity. Toxicol. Appl. Pharmacol. 266, 198–203 (2013). PubMed DOI

Dong, H. et al. Quantitative determination of aristolochic acid-derived DNA adducts in rats using PubMed DOI

Mei, N., Arlt, V. M., Phillips, D. H., Heflich, R. H. & Chen, T. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat. Res. Fund. Mol. Mech. Mutagen. 602, 83–91 (2006). DOI

Quan, Y. et al. Assessment of nephrotoxicity of herbal medicine containing aristolochic acid in mice. Korean J. Intern. Med. 35, 400 (2020). PubMed DOI

Arlt, V. M. et al. Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int. J. Cancer 128, 21–32 (2011). PubMed DOI

Baudoux, T. et al. CD4 DOI

Zhou, L. et al. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am. J. Physiol. Ren. Physiol. 298, F1006–F1017 (2010). DOI

Ye, J. et al. Aristolochic acid I aggravates renal injury by activating the C3a/C3aR complement system. Toxicol. Lett. 312, 118–124 (2019). PubMed DOI

Ding, Y.-J. & Chen, Y.-H. Developmental nephrotoxicity of aristolochic acid in a zebrafish model. Toxicol. Appl. Pharmacol. 261, 59–65 (2012). PubMed DOI

Chen, T. et al. Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats. BMC Bioinform. 7 (Suppl. 2), S20 (2006). DOI

Grollman, A. P. & Jelaković, B. Role of environmental toxins in endemic (Balkan) nephropathy. J. Am. Soc. Nephrol. 18, 2817 (2007). PubMed DOI

Zhou, Y. et al. Aristolochic acid causes albuminuria by promoting mitochondrial DNA damage and dysfunction in podocyte. PloS ONE 8, e83408 (2013). PubMed DOI PMC

Romanov, V., Whyard, T. C., Waltzer, W. C., Grollman, A. P. & Rosenquist, T. Aristolochic acid-induced apoptosis and G2 cell cycle arrest depends on ROS generation and MAP kinases activation. Arch. Toxicol. 89, 47–56 (2015). PubMed DOI

Correa-Rotter, R. & García-Trabanino, R. Mesoamerican nephropathy. Semin. Nephrol. 39, 263–271 (2019). PubMed DOI

Wijkstrom, J. et al. Renal morphology, clinical findings, and progression rate in Mesoamerican nephropathy. Am. J. Kidney Dis. 69, 626–636 (2017). PubMed DOI

Gifford, F. J., Gifford, R. M., Eddleston, M. & Dhaun, N. Endemic nephropathy around the world. Kidney Int. Rep. 2, 282–292 (2017). PubMed DOI

Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246–259 (2013). PubMed DOI PMC

Koh, G., Degasperi, A., Zou, X., Momen, S. & Nik-Zainal, S. Mutational signatures: emerging concepts, caveats and clinical applications. Nat. Rev. Cancer 21, 619–637 (2021). PubMed DOI

Senkin, S. MSA: reproducible mutational signature attribution with confidence based on simulations. BMC Bioinforma. 22, 540 (2021). DOI

Degasperi, A. et al. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat. Cancer 1, 249–263 (2020). PubMed DOI PMC

Koh, G., Zou, X. & Nik-Zainal, S. Mutational signatures: experimental design and analytical framework. Genome Biol. 21, 37 (2020). PubMed DOI PMC

Melki, P. N., Korenjak, M. & Zavadil, J. Experimental investigations of carcinogen-induced mutation spectra: innovation, challenges and future directions. Mutat. Res. Genet. Toxicol. Env. Mutagen. 853, 503195 (2020). DOI

Zavadil, J. & Rozen, S. G. Experimental delineation of mutational signatures is an essential tool in cancer epidemiology and prevention. Chem. Res. Toxicol. 32, 2153–2155 (2019). PubMed DOI

Zou, X. et al. Validating the concept of mutational signatures with isogenic cell models. Nat. Commun. 9, 1744 (2018). PubMed DOI PMC

Wu, Y., Chua, E. H. Z., Ng, A. W. T., Boot, A. & Rozen, S. G. Accuracy of mutational signature software on correlated signatures. Sci. Rep. 12, 390 (2022). PubMed DOI PMC

The Mutographs biorepository: A unique genomic resource to study cancer around the world